Pfizer advances vision for future of cancer care at ASCO 2025 Annual Meeting

Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion

The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience

Zydus Medtech inks pact with Braile Biomedica to commercialise TAVI technology

Zydus MedTech gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets

Morepen to add 1,000 medical representatives

The company is targeting a Rs. 1,000 crore finished dosages business within the next five years

Granules India completes acquisition of Senn Chemicals

Strengthening capabilities in Peptide Therapeutics and CDMO services

Alife expands personal care portfolio with Gondhoraj & Neem soap in West Bengal

The unique soap-fusion of Gondhoraj lime and neem provides a refreshing skin-friendly experience

Metropolis to acquire Dehradun’s Ahujas’ Pathology & Imaging Centre for Rs. 35.01 Cr

Lupin acquires UK-based Renascience Pharma for £12.3 million

The portfolio includes branded injectable cephalosporines for infectious diseases

Mankind unveils HealthOK’s 100% vegetarian multivitamin tablets campaign with Archana Puran Singh

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy